Effects of bolesatine on a cell line from the SP2/O thymic lymphosarcoma.
Bolesatine, a toxic protein isolated from Boletus satanas Lenz inhibits in vitro protein synthesis in a concentration-dependent manner in a cell line from a radiation-induced thymic lymphosarcoma (SP2/O) with a 50% inhibitory concentration (IC50) of 9.5 nM (0.6 microgram/ml). In vivo, an i.p. single injection of bolesatine, corresponding to 1/6 and 1/10 of 24-h 50% lethal dose, in Balb/c mice having ascitic tumour induced by the i.p. preinjection of SP2/O cells allows a remission of 50% and 30%, respectively. Treated mice survived 120 days after the treatment, i.e. 90 days after the death of control animals.
University of Bordeaux 2, Faculty of Pharmaceutical Sciences, Laboratory of Toxicology and Applied Hygiene, France.
L
L
Basset
R
R
Ennamany
J P
JP
Portail
O
O
Kretz
G
G
Deffieux
A
A
Badoc
B
B
Guillemain
E E
EE
Creppy
D000818:Animals; D002455:Cell Division / Q000187:drug effects; D002470:Cell Survival / Q000187:drug effects; D004305:Dose-Response Relationship, Drug; D005260:Female; D005656:Fungal Proteins / Q000008:administration & dosage / Q000627:therapeutic use / Q000633:toxicity*; D007274:Injections, Intraperitoneal; D007700:Kinetics; D007928:Lethal Dose 50; D008228:Lymphoma, Non-Hodgkin / Q000188:drug therapy / Q000401:mortality / Q000473:pathology*; D008297:Male; D051379:Mice; D008807:Mice, Inbred BALB C; D009183:Mycotoxins; D009381:Neoplasms, Radiation-Induced / Q000188:drug therapy / Q000401:mortality; D011500:Protein Synthesis Inhibitors / Q000627:therapeutic use / Q000633:toxicity*; D013953:Thymus Neoplasms / Q000188:drug therapy / Q000401:mortality / Q000473:pathology*; D014407:Tumor Cells, Cultured / Q000187:drug effects
D005656:Fungal Proteins; D009183:Mycotoxins; D011500:Protein Synthesis Inhibitors; C060924:Bolesatine protein, Boletus satanas